174 results about "Thrombolytic drug" patented technology

An apparatus and method for using ultrasound augmented with microbubbles, thrombolytic drugs or other agents for clot lysis wherein at least one ultrasound transducer generates a plurality of acoustic signals and time, amplitude, phase and frequency modulation of the signals provide more uniform power delivery with fewer gaps in the ultrasound field. Interference patterns from one or multiple transducers are constantly shifted in position. A phased array of transducers may generate a beam that is swept over the area to be treated. In another embodiment, an array of transducers may generate ultrasound at a number of slightly varying frequencies to produce an interference pattern that sweeps in and out through the targeted tissue. A single array may be used to produce both effects simultaneously or separately.

A therapeutic device and method for use thereof for treatment of blood flow disorders is disclosed. In one embodiment, a first line emergency response system for treatment of acute thrombotic and/or vasospastic vascular obstructions via the noninvasive application of low frequency vibration with at least one, and preferably a plurality of randomly administered vibratory waveform characteristics (herein after “Randomic Vibration”) is detailed. The disclosed apparatus and methods are based on the intuition that transcutaneously imparted low frequency randomic vibration can provide enhanced clot disruption and mixing of clot disruptive agents to acutely thrombosed vessels, due to the addition of mechanical chaos via non-regular, multi-vectored convection currents. In a preferred embodiment, the disclosed apparatus and methods preferably utilize randomic vibration as an adjunct to systemically administered drug therapy, most preferably intravenously administered thrombolytic drug therapy.

Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

The invention discloses a functional platelet bionic intelligent carrier and application thereof in anti-ischemic cerebral apoplexy. The bionic carrier is composed of polymer nanoparticles of a platelet membrane coated neuroprotectant ZL006e, a Tat cell-penetrating peptide as well as substrate peptide fragments and fibrinolytic protein conjugates capable of being cut by thrombin. The carrier system has the characteristics of excellent biocompatibility, capacity of effectively prolonging in-vivo cycle time and the like, and is capable of targeting micro-thrombus in lesions of ischemic cerebralapoplexy and releasing thrombolytic drugs. Meanwhile, the exposed Tat cell-penetrating peptide mediated neuroprotectant is capable of increasing blood-brain barrier permeability, the pH serves as an intelligent drug release switch, and the pH-mediated degradation at the lesions is responded, so that the drug is quickly released at lesions of cerebral ischemia, the curative effects are improved tothe greatest degree, and toxic and side effects are reduced.

A rotary catheter comprising a motor-driven flexible shaft rotatably disposed in a flexible tube having a fluid channel between them, a distal portion of the flexible shaft extending out of the tube and being free to move radially relative to the tube enabling the fluid channel to ingest large particles eased by motions between the rotating flexible shaft and the flexible tube, and pump means containing a thrombolytic drug connected to the fluid channel for infusing the drug through the fluid channel to the obstruction. An asymmetrical tip that is affixed to a distal end of the shaft has a substantially narrower cross section than its effective diameter so that fluid can flow alongside the tip and reach the area that the tip impacts the obstruction with the side of the tip and the tube aspirates fluid and the resulting particles into the channel.

The invention provides a thrombus thrombolysis and clearing device and a use method thereof, and relates to the technical field of a medical appliance. The invention aims at solving the problems thatan existing thrombus clearing device is difficult to clear the thrombus on the vascular wall, so that the thrombus clearing is unthorough. A thrombus suction head in the thrombus thrombolysis and clearing device provided by the invention is arranged on a fixed cutter holder and is rotationally connected with the fixed cutter holder; a transmission tube is arranged in an outer tube in a sleeved way; the end, provided with a through hole, of the transmission tube extends out of the outer tube; a liquid cavity bag is arranged on the outer tube wall of the outer tube between a baffle edge and a baffle ring; a sliding seat is arranged on the transmission tube in a sleeving way and is glidingly connected with the transmission tube; the sliding seat is positioned between the baffle edge and the baffle ring; and a thrombus breaking cutter is fixedly arranged between the fixed cutter holder and the sliding seat. According to the thrombus thrombolysis and clearing device, pressurized normal saline or thrombolysis medicine is sprayed out from the liquid cavity bag to break the thrombus; meanwhile, a driver drives the transmission tube to rotate at a high speed; the thrombus breaking cutter onthe sliding seat is driven to perform rotary cutting on the thrombus; and the tensioned thrombus breaking cutter can scrape away the thrombus on the vascular wall. The thrombus thrombolysis and clearing device and the use method provided by the invention are applied to the field of medical care.

An apparatus and method for automatically lysing a clot to recanalize vessels using ultrasound, with or without nanoparticles, microbubbles, thrombolytic drugs or other agents, is described herein. At least one ultrasound transducer with a specified geometry, bandwidth and/or transmit pulse characteristics can generate a more uniform 3-dimensional volume of defocused acoustic energy into a target area of the body. When an agent (such as, but not limited to, microbubbles) is used to lyse a clot, a certain level of ultrasound energy may be desired in order to effect certain actions or states of the agent. Bone attenuation may present an issue inhibiting sufficient ultrasound energy from reaching the agent in order to attain the desired agent action. The relative patient dimensions and location of the clot may also present an issue.

The invention discloses a fibrinolytic activated protein from cantharis, a preparation method and an application thereof. In the invention, the single-component protein with fibrinolytic activity is extracted from the cantharis, and the molecular weight of the protein is 95.5KD; and the protein has the advantages of easy purification and batch preparation, stronger fibrinolytic activity, high specific activity, no toxicity, small molecular weight and low antigen reaction, thus being an ideal plasmin preparation raw material as well as an ideal thrombolytic drug. The invention further discloses the preparation method of the fibrinolytic activated protein and the application of the same for preparing the drug for treating thrombotic disease.

The invention relates to the technical field of medical apparatuses and instruments, in particular to a universal thrombus smashing and extracting device with biomimetic jellyfish contraction and expansion functions. The device comprises a spraying mechanism used for spraying a thrombolytic drug, a thrombus smashing and extracting mechanism used for guiding thrombus out and connected with the spraying mechanism, a guiding mechanism used for pushing the spraying mechanism to go into a human body lumen and a power mechanism used for driving the guiding mechanism to move. According to the universal thrombus smashing and extracting device with the biomimetic jellyfish contraction and expansion functions, the spraying mechanism can go into the human body lumen by means of the guiding mechanism,then the thrombolytic drug is sprayed by the spraying mechanism so that thrombolysis can be conducted, the thrombus is smashed and extracted by the thrombus smashing and extracting mechanism, operation is convenient, the thrombus elimination speed is high, and the efficiency is high.

The invention relates to the field of biomedicine, in particular to a preparation method of snake venom thrombin-like protein. Firstly, the venom tissue of Agkistrodon akistrosus is isolated, and a phage display library is constructed. Using fibrin/fibrinogen as a substrate, three rounds of panning selected, a new thrombin-like gene from Agkistrodon venom was obtained. The present invention also constructs the prokaryotic expression vector pET-32(a)-TLE of the viper venom thrombin gene of Agkistrodon akistrodon, and obtains the recombinant snake venom thrombin with biological activity after induced expression, affinity purification and molecular sieve purification protein. The enzyme can be used to prepare cardiovascular thrombolytic drugs.

The present invention relates to a hemostasis valve device which allows a wire or a catheter to be inserted into the left or right coronary artery via the femoral artery or an arm artery when a Cardiac Catheterization or Percutaneous Transluminal Coronary Angioplasty operation is performed, wherein two independent sealing members are opened and closed by press and release actions of push buttons coupled to a body and the rotation of a fastening tube, respectively, so that the leakage or blood or the inflow of outside air is simply and effectively blocked during the operation, and a drug influx tube for allowing a medicine such as a thrombolytic drug to flow into a patient during the operation pivots and is adjusted in a stepwise manner within a certain range of angles according to body conditions or movements of the patient.

The invention discloses a thrombolytic/platelet aggregation inhibiting dual-function molecule and uses thereof. The thrombolytic/platelet aggregation inhibiting dual-function molecule is a mutant of Fibrolase (substitution of 69-74 amino acid sequence T(Thr)-S(Ser)-V(Val)-S(Ser)-H(His)-D(Asp) of Fibrolase with G(Gly)-P(Pro)-R(Arg)-G(Gly)-D(Asp)-W(Trp)-R(Arg)-M(Met)-L(Leu)-G(Gly)) containing a RGD sequence. The invention also discloses a preparation method. The inventive Fibrolase mutant can be used a novel thrombolytic drug, and has thrombolytic and platelet aggregation inhibiting functions.

The invention provides an interventional ultrasonic thrombolysis device. The interventional ultrasonic thrombolysis device comprises a catheter body, an ultrasonic transducer and an insulating shell, wherein the catheter body comprises an outer tube and an inner tube, and the outer tube is arranged on the outer side of the inner tube in a sleeving mode; the ultrasonic transducer is arranged at the end of the catheter body in a sleeving mode, and is suitable for generating ultrasonic waves in the radial direction of the catheter body; and the insulating shell seals a shell of the ultrasonic transducer. According to the device, the ultrasonic transducer polarized in the thickness direction is used for applying ultrasound to the end of the thrombus, the ultrasound generates a cavitation effect to tear the thrombus, ultrasonic energy promotes permeation of a thrombolysis drug to the thrombus, the action area of the thrombolysis drug is increased, thrombolysis is accelerated, and the thrombus is dissolved from head to tail; and with adoption of non-plug-in mode for thrombolysis, the device has small damage to blood vessels and is especially suitable for old thrombus.

A vena cava filter device capable of releasing a thrombolytic drug is characterized in that a drug release head with a plurality of irregular holes is arranged in the center of a filter, the drug release head and a drug conveying pipe are connected and arranged in a filter body connecting pipe, and one end of the drug conveying pipe is provided with a drug injection hole. According to the vena cava filter device, thrombi are stopped by the vena cava filter, the thrombolytic drug is injected into the drug conveying pipe in the a filter body connecting pipe through the drug injection hole, and if the thrombi are stopped by the vena cava filter, the thrombolytic drug is directly injected to the thrombi through the irregular holes; it is not needed that venipuncture is carried out on a patient again to achieve thrombolysis, so that secondary injuries to the patient are reduced and risks brought by venipuncture to the patient are avoided; the vena cava filter device has the dual effects of stopping the thrombi and achieving thrombolysis.

The invention relates to a method for preparing a thrombolytic medicament Reteplase (rPA) directly through an escherichia coli expression system without inclusion-body renaturation. A gene segment of the rPA is obtained through PCR amplification, and is cloned into a vector pET40b to construct a pET40b-rPA recombinant plasmid, and the rPA is made to perform fusion expression with the protein disulfide isomerase DsbC in the vector pET40b. The recombinant plasmid is transformed into the escherichia coli BL21 (DE3), and induction expression conditions of IPTG and lactose are respectively established optimally. The obtained target fusion protein is mainly expressed by soluble components, and is purified by Ni-NTA affinity chromatography and processed by a Xa factor (or formic acid or thrombin) to form the high-purity rPA target protein. Fibrin plate method detection results show that the fusion protein DsbC-rPA obtained by the method and the rPA protein obtained by removing a label and purifying have obvious thrombolytic activity.

The present invention relates to the use of plasminogen in the dissolution of fresh and old thrombus. Compared with other existing thrombolytic drugs, the plasminogen of the present invention can specifically dissolve thrombus without causing side effects such as bleeding. The drug of the present invention also has the advantages of dissolving both fresh and old thrombus, with a long half-life and controllable thrombolytic strength. Therefore, plasminogen may become a brand-new strategy for dissolving thrombus in vivo.

The invention relates to a pH responsive thrombolytic drug targeting nanogel, a synthesis method and application thereof. The nanogel is formed by covalent linkage of a thrombolytic drug and oxidative dextran through a pH sensitive imine linkage and introduction of a thrombus-targeted ligand to an oxidative dextran molecular chain. The imine linkage is stable under normal physiological pH value, and can hydrolyze under a weak acid pH value. The thrombus-targeted ligand enables the nanogel with thrombus active targeting ability, is stable in a circulation system, and releases drug molecules after reaching an embolism part, thus reducing the risk of body bleeding caused by the thrombolytic drug. The nanogel has reversible biological properties. By regulating the molecular weight, reaction ratio and functional group of the polymer, the hydrolysis resistant degree and opportunity of thrombolytic drug protein molecules to hydrolase can be regulated, and also activity release to drug molecules can be controlled. The microsystem can be used as a thrombolytic drug carrier for transportation of protein or peptide drugs so as to realize synergistic treatment of drugs.

The invention discloses four (R)-6, 7-dihydroxy-1, 1-dimethyl isochroman-3-formyl-AA (AA is L-Phe, L-His, L-Trp and L-Tyr residues) of the following formula, a preparation method thereof and an application of the (R)-6, 7-dihydroxy-1, 1-dimethyl isochroman-3-formyl-AA in thrombolytic drug preparation. Therefore, the invention discloses an application of the compounds in preparation of thrombolyticdrugs.

The invention discloses a surgical robot for treating thrombus. The surgical robot is characterized by comprising a thrombus clearing device and a fixing device, wherein the thrombus clearing device comprises a needle tube, a liquid feeding pipe and an inner core; the needle tube is provided with a tube cavity; an opening is formed in one end of the needle tube and a three-way valve is arranged at the other end of the needle tube; the inner core can penetrate through the three-way valve to be arranged in the tube cavity of the needle tube in an inserting and plugging manner, and stretches out from the opening; the end part of the liquid feeding pipe is connected with the three-way valve; the three-way valve is used for controlling the communicating and closing of the liquid feeding pip and the needle tube; the fixing device is used for mounting the thrombus clearing device; the fixing device is movably arranged. The surgical robot for treating the thrombus, disclosed by the invention, can be used for mechanically clearing a thrombus and crushing the thrombus, and a thrombolytic drug can also be injected to dissolve the thrombus, so that the thrombus treatment effect is good and the operation precision is high; the surgical robot for treating the thrombus is especially suitable for high-precision surgical operation.

The invention discloses a preparation method for a nanometer preparation of a thrombolytic drug released under temperature control. The method comprises the following steps: taking a thermosensitive magnetic lipidosome as a drug carrier, utilizing a targeting effect of an outside magnetic field to directionally convey the thermosensitive magnetic lipidosome to a thrombus focus and utilizing a magnetic heating effect of an alternating magnetic field to magnetic ferroferric oxide nano-particles to control the release of the thrombolytic drug, thereby realizing the safe conveying and controlled release of the thrombolytic drug. The preparation method has the advantages: 1) the thermosensitive magnetic lipidosome which has already passed the authentication of Food and Drug Administration is used as the drug carrier, so that the thrombolytic drug has excellent biocompatibility; 2) the nanometer preparation can control the release of the thrombolytic drug under the effect of the outside alternating magnetic field; 3) the guiding effect of the magnetic field is utilized to directionally convey the nanometer preparation to the thrombus focus; 4) the overheating generated by the magnetic ferroferric oxide nano-particles under the induction of the alternating magnetic field can promote the thrombus dissolution.

The invention discloses a thrombus-targeted long-cycle sustained release liposome and a preparation method thereof and belongs to the technical field of drug controlled release and biological materials. The thrombus-targeted long-cycle sustained release liposome comprises a drug-loading sustained release liposome as well as a platelet membrane and distearoyl phosphoethanolamine-polyethylene glycol, wherein the drug-loading sustained release liposome is composed of a thrombolytic drug, star cholic acid functionalized poly(lactic acid), soyabean lecithin and cholesterol; the platelet membrane and distearoyl phosphoethanolamine-polyethylene glycol cover the drug-loading sustained release liposome in a staggered manner. The preparation method disclosed by the invention comprises the followingsteps: introducing the star cholic acid functionalized poly(lactic acid) into a thrombolytic drug long-cycle liposome, and modifying the platelet membrane and distearoyl phosphoethanolamine-polyethylene glycol, thereby obtaining the thrombus-targeted long-cycle sustained release liposome. The defects that the conventional thrombosis drug needs frequent dosing, the curative effects are poor and thecost is high are overcome, and the thrombus-targeted long-cycle sustained release liposome has the advantages of being excellent in thrombus targeting property, excellent in sustained release effect,long in half-life in vivo, obvious in thrombolytic effect, high in stability, excellent in biocompatibility and the like.

The invention discloses application of salvianolic acid A in preparation of a drug for treating cerebral hemorrhage. Cerebral hemorrhage comprises simple cerebral hemorrhage stroke, hemorrhage after cerebral embolism and hemorrhage caused by thrombolytic drug treatment and other factors. Experimental research finds that salvianolic acid A can significantly reduce the cerebral infarction volume andencephaledema of rats, improve neurological functions and protect blood-brain barrier damage caused by thrombolytic drugs such as t-PA, thereby reducing the risk and degree of hemorrhagic transformation when the thrombolytic drugs are used. The salvianolic acid A can be used for preparing the drug for treating cerebral hemorrhage and hemorrhage caused by thrombolytic drug treatment, relieving secondary hemorrhage in ischemic areas and improving prognosis of patients.